STORM

Global $5.5 Bn Super-resolution Microscopes (STED, STORM, SIM, PALM, FPALM) Markets to 2028 - ResearchAndMarkets.com

Friday, October 15, 2021 - 2:29pm

Increasing application in cell biology and biomedical imaging and technological advancements are factors expected to drive the market over the forecast period.

Key Points: 
  • Increasing application in cell biology and biomedical imaging and technological advancements are factors expected to drive the market over the forecast period.
  • The SIM technology segment is projected to account for the largest market share by 2028.
  • STORM technology is estimated to register the fastest CAGR from 2021 to 2028.
  • The U.S. is one of the leading markets owing to technological advancements and surging R&D expenditure.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

ALAMEDA, Calif. and CAMBRIDGE, England, Oct. 14, 2021 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target. 

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:00pm

Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.
  • STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline, said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

DGAP-News: OTRS AG publishes half-year report 2021: Double-digit growth rates in revenue and earnings

Thursday, September 30, 2021 - 9:03am

OTRS AG publishes half-year report 2021: Double-digit growth rates in revenue and earnings

Key Points: 
  • OTRS AG publishes half-year report 2021: Double-digit growth rates in revenue and earnings
    The issuer is solely responsible for the content of this announcement.
  • OTRS AG publishes half-year report 2021: Double-digit growth rates in revenue and earnings
    - EBITDA increases by 38% to EUR 1,451 thousand (H1 2020: EUR 1,053 thousand)
    Oberursel, September 30, 2021: OTRS AG (ISIN: DE000A0S9R37 ) today published its half-year report 2021.
  • With OTRS 8 and STORM powered by OTRS, OTRS AG serves a continuously increasing demand for innovative software and IT security solutions.
  • The company consists of OTRS AG and its six subsidiaries OTRS Inc. (USA), OTRS S.A. de C.V. (Mexico), OTRS Asia Pte.

L3Harris to Deliver Enhanced Night Vision Goggle Technology to the US Army

Thursday, September 16, 2021 - 2:00pm

The U.S. Army has awarded L3Harris Technologies (NYSE:LHX) a $100 million order for the Enhanced Night Vision Goggle Binocular (ENVG-B) system that will enhance soldier situational awareness, mobility, survivability and lethality.

Key Points: 
  • The U.S. Army has awarded L3Harris Technologies (NYSE:LHX) a $100 million order for the Enhanced Night Vision Goggle Binocular (ENVG-B) system that will enhance soldier situational awareness, mobility, survivability and lethality.
  • Since 2018, L3Harris has delivered more than 6,000 ENVG-B systems to the Army as part of both the POR and Directed Requirements contracts.
  • ENVG-B is todays most advanced, combat-ready situational awareness goggle and delivers game changing technology to the Armys close combat forces.
  • Im proud of the important role New Hampshire plays in safeguarding our national security, including this award for L3Harris Technologies in Londonderry to produce enhanced night vision goggles.

IDEMIA Brings Cutting-Edge Fingerprint-Matching Algorithms to Local Law Enforcement Agencies

Monday, September 13, 2021 - 1:53pm

RESTON, Va., Sept. 13, 2021 /PRNewswire/ -- IDEMIA, the biometric solutions leader for law enforcement agencies, announced today it has launched the world's first SaaS-based Automated Biometric Identification System (ABIS), IDEMIA STORM ABIS, for intuitive, accessible and affordable fingerprint analysis, comparison and documentation.

Key Points: 
  • RESTON, Va., Sept. 13, 2021 /PRNewswire/ -- IDEMIA, the biometric solutions leader for law enforcement agencies, announced today it has launched the world's first SaaS-based Automated Biometric Identification System (ABIS), IDEMIA STORM ABIS, for intuitive, accessible and affordable fingerprint analysis, comparison and documentation.
  • IDEMIA STORM ABIS is an intuitive web-based platform that allows for efficient access to world-class fingerprint-matching technology.
  • It supports local and national searches with tools for analysis, comparison and case management that allows fingerprint examiners to efficiently complete examinations from anywhere.
  • "Designed from the ground up by fingerprint examiners for examiners, STORM will transform how we deliver automated fingerprint identification capabilities to our law enforcement customers."

Swiss Re Corporate Solutions expands parametric tropical cyclone insurance with risk data provider Reask

Tuesday, August 31, 2021 - 1:30am

ZURICH, Aug. 30, 2021 /PRNewswire/ --Swiss Re Corporate Solutions has teamed up with Reask, a tropical cyclone risk analytics firm, to expand its parametric windstorm solution, STORM.

Key Points: 
  • ZURICH, Aug. 30, 2021 /PRNewswire/ --Swiss Re Corporate Solutions has teamed up with Reask, a tropical cyclone risk analytics firm, to expand its parametric windstorm solution, STORM.
  • The insurer will leverage Reask's advanced technological windspeed data to provide tropical cyclone coverage to corporate and public entities exposed to the peril.
  • Metryc, Reask's tropical cyclone risk modelling product, is built to address the specific requirements of nat cat parametric insurance contracts.
  • "Tropical cyclones continue to pose a major risk," says Martin Hotz, Head Parametric Nat Cat at Swiss Re Corporate Solutions.

Senate bill takes first step in recognizing buildings as infrastructure

Wednesday, August 11, 2021 - 6:07pm

"This bipartisan legislation represents an important step toward improving our nation's buildings.

Key Points: 
  • "This bipartisan legislation represents an important step toward improving our nation's buildings.
  • The Senate is expected to advance a second infrastructure bill through the Budget Reconciliation process this fall.
  • AIA has advocated for several of the provisions included in the Senate's "Infrastructure Investment and Jobs Act," ( H.R.
  • Since February, the AIA and its members have been advocating for members of Congress to include federal funding for buildings in the infrastructure package.